Global Fabry Disease - Competitive Analysis 2019

Global Fabry Disease - Competitive Analysis 2019

Global Fabry Disease - Competitive Analysis 2019

$ 1,500
$1,950
$2,550

Published: Jun-2019

Pages:95

Table:46

Figure:19

Report ID:UMHE19154

Fabry Disease (also known as Anderson Fabry Disease) is a progressive X linked inherited genetic disorder of glycosphingolipid metabolism due to deficient or absent lysosomal α-galactosidase A activity. It is a devastating inborn error of metabolism with, particularly in the early stages, being played by cellular dysfunction and microvascular pathology being induced by lysosomal glycosphingolipid deposition. The absence or deficient activity of lysosomal exoglycohydrolase α-galactosidase A results in the progressive accumulation of globotriaosylceramide and related glycosphingolipids within lysosomes which are ubiquitous subcellular organelles.

The first clinical symptoms interfering with the child's well-being and performance arise in childhood, typically between the ages of 3 and 10 years, and generally a few years later in girls than in boys. With age, progressive damage to vital organ systems develops in both genders leading to organ failure. End-stage renal disease and life-threatening cardiovascular or cerebrovascular complications limit life-expectancy. The clinical signs are multisystemic, heterogeneous, and progressive.

Split of Therapeutic Products

 

The biochemical diagnosis of Fabry Disease is established by measuring α-gal A activity in plasma or leukocytes taken from peripheral blood, cultured fibroblasts or using the samples extracted from the filter paper blood spots. The diagnosis of FD can arise from careful clinical and instrumental investigations, together with family history data and accurate interpretation of genetic and enzymatic analyses. Identification of a hemizygous GLA pathogenic variant by molecular genetic testing confirms the diagnosis in a male proband.

There are 2+ products approved for the treatment of Fabry Disease. The therapeutic pipeline of Fabry Disease consists of approximately 9+ products in different stages of development. Currently, 2+ drugs are in Phase III development and major drugs are in pre-clinical stage.

Top Company Analysed

Some of the key players include Amicus Therapeutics; Evotec; Freeline; Greenovation Biotech; Idorsia Pharmaceuticals; Moderna; Pharming; Protalix Biotherapeutics; Resverlogix Corp; Sangamo Therapeutics and Sanofi Genzyme.

Scope of the study:

  • The report provides the marketed drugs information including its approval details, development activities and details of patent expiry
  • Provides an overview of therapeutic pipeline activity for Fabry Disease across the complete product development cycle including all clinical and non-clinical stages
  • The report comprises of detailed profiles of Fabry Disease therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Detailed profiles of the dormant products have been included in the report

Reasons to buy:

  • The Fabry Disease competitive report presents the detailed profile of drugs. The analysis offered in the report is a combination of deep dive secondary research and input from Key Opinion Leader of the industry
  • The report presents a quick review of the current scenario regarding the drug development of the indication at one glance
  • The report covers in-depth analysis of prominent industry peers with a primary focus on company consolidation, designation, technology, agreements and patents regarding the therapy
  • Detailed examination on diagnosis, treatment and guidelines prevailing in the industry
  • Examination of industry attractiveness with the help of approval timelines
  • The study comprehensively covers the market across drugs in different phases of development
  • Extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the dormancy of the products

Customization Options:

The Fabry Disease competitive analysis report can be customized to the country level or any other competitive segment. Besides this, UMI understands that you may have your own business need, hence we also provide fully customized solutions to clients.

             
  1 REPORT INTRODUCTION
    1.1 Objective of the Study
    1.2 Secondary Research
    1.3 Scope of the report:
  2 DISEASE OVERVIEW  
    2.1 Introduction  
    2.2 Etiology    
    2.3 Classification  
    2.4 Signs and Symptoms
      2.4.1 The early and progressive clinical symptoms include:
    2.5 Pathogenesis  
      2.5.1 Metabolic Defect
      2.5.2 The Molecular Basis
      2.5.3 Genotype/Phenotype Correlation
    2.6 Diagnosis    
      2.6.1 Biochemical Diagnosis:
        2.6.1.1 Measurement of a-Gal Activity in Cultivated Fibroblasts, Plasma, or Leukocytes
        2.6.1.2 Measurement of α-Gal A Activity in Blood Spot Filter Paper
        2.6.1.3 GL-3 Levels
      2.6.2 Molecular Diagnosis
      2.6.3 Molecular Analysis
    2.7 Treatment  
      2.7.1 Clinical management of pediatric patients
      2.7.2 Management of Fabry related pain in pediatric patients
        2.7.2.1 Trigger management
        2.7.2.2 Symptomatic therapy
        2.7.2.3 Management of neuropathic pain
        2.7.2.4 Management of psychological disturbances
      2.7.3 Treatment Algorithm for the management of neuropathic pain in paediatric Fabry Disease patients
        2.7.3.1 Enzyme replacement therapy
        2.7.3.2 Recommendations for ERT initiation
      2.7.4 Management in adults
        2.7.4.1 Available Enzyme Replacement therapies
        2.7.4.2 Initiation of enzyme replacement therapy
        2.7.4.3 Expert panel recommendations for initiation of enzyme replacement therapy in adult patients with Fabry Disease
        2.7.4.4 Adjunctive therapies
        2.7.4.5 Non-ERT approaches for patients with specific mutations
      2.7.5 Monitoring of adult patients with Fabry Disease
  3 PRODUCTS UNDER DEVELOPMENT BY TECHNOLOGY
  4 PRODUCTS UNDER DEVELOPMENT BY DESIGNATION
    4.1 Comparative Analysis
  5 TOTAL NUMBER OF MARKETED AND EMERGING PRODUCTS
    5.1 Comparative Analysis
  6 MARKETED PRODUCTS
    6.1 Galafold: Amicus Therapeutics
      6.1.1 Product Description
        6.1.1.1 Dosage and Administration:
      6.1.2 Regulatory Milestones
        6.1.2.1 Approval
      6.1.3 Research and Development
        6.1.3.1 Clinical Studies
          6.1.3.1.1 Clinical Studies
          6.1.3.1.2 Results of Analysis
      6.1.4 Product Development Activities
        6.1.4.1 Positive Recommendation
        6.1.4.2 Designation
        6.1.4.3 Patents
        6.1.4.4 Licensing
          6.1.4.4.1 GlaxoSmithKline
          6.1.4.4.2 Mt. Sinai School of Medicine
    6.2 Replagal: Shire  
      6.2.1 Product Description
        6.2.1.1 Dosage and Administration:
      6.2.2 Regulatory Milestones
        6.2.2.1 Approval
      6.2.3 Research and Development
        6.2.3.1 Clinical Studies
      6.2.4 Product Development Activities
        6.2.4.1 BLA Withdrawn
        6.2.4.2 Business Expansion
        6.2.4.3 Acquisition
        6.2.4.4 Designation
    6.3 Fabrazyme: Sanofi Genzyme
      6.3.1 Product Description
        6.3.1.1 Dosage and Administration:
      6.3.2 Regulatory Milestones
        6.3.2.1 Approval
      6.3.3 Research and Development
        6.3.3.1 Clinical Studies
      6.3.4 Product Development Activities
        6.3.4.1 Designation
  7 PIPELINE THERAPEUTICS AT A GLANCE
    7.1 General Overview
  8 COMPARATIVE ANALYSIS
    8.1 General Overview
  9 LATE PHASE PRODUCTS (PHASE III)
    9.1 Comparative Analysis
    9.2 Lucerastat: Idorsia Pharmaceuticals
      9.2.1 Product Description
      9.2.2 Research and Development
        9.2.2.1 Clinical Studies
          9.2.2.1.1 Phase III
          9.2.2.1.2 Phase I
          9.2.2.1.3 Results of Analysis
          9.2.2.1.4 Results of Analysis II
      9.2.3 Product Development Activities
        9.2.3.1 Designation
        9.2.3.2 Spin Off
    9.3 Pegunigalsidase alfa: Protalix Biotherapeutics
      9.3.1 Product Description
      9.3.2 Research and Development
        9.3.2.1 Clinical Studies
          9.3.2.1.1 Phase III
          9.3.2.1.2 Results of Analysis
          9.3.2.1.3 Results of Analysis II
      9.3.3 Product Development Activities
        9.3.3.1 Designation
        9.3.3.2 Agreement
        9.3.3.3 Patent
        9.3.3.4 Technology
  10 MID PHASE PRODUCTS (PHASE II)
    10.1 Comparative Analysis
    10.2 Venglustat: Sanofi Genzyme
      10.2.1 Product Description
      10.2.2 Research and Development
        10.2.2.1 Clinical Studies
          10.2.2.1.1 Phase II
    10.2.3 Product Development Activities
      10.2.3.1 Designation
  11 EARLY STAGE PRODUCTS (PHASE I)
    11.1 Comparative Analysis
    11.2 Apabetalone: Resverlogix Corp
      11.2.1 Product Description
      11.2.2 Research and Development
        11.2.2.1 Clinical Studies
          11.2.2.1.1  
    11.3 Moss-aGal: Greenovation Biotech
      11.3.1 Product Description
      11.3.2 Research and Development
        11.3.2.1 Clinical Studies
          11.3.2.1.1  
          11.3.2.1.2  
      11.3.3 Product Development Activities
        11.3.3.1 Technology
  12 PRE-CLINICAL STAGE PRODUCTS
    12.1 Comparative Analysis
    12.2 Fabry Gene Therapy: Amicus Therapeutics
      12.2.1 Product Description
      12.2.2 Product Development Activities
        12.2.2.1 Agreement
    12.3 FTL190: Freeline
      12.3.1 Product Description
      12.3.2 Research and Development
        12.3.2.1 Pre-clinical Studies
      12.3.3 Product Development Activities
      12.3.3.1 Financing  
    12.4 mRNA-3630: Moderna
      12.4.1 Product Description
    12.5 PGN005 (α-galactosidase): Pharming
      12.5.1 Product Description
    12.6 ST-920: Sangamo Therapeutics
      12.6.1 Product Description
      12.6.2 Research and Development
        12.6.2.1 Pre-clinical Studies
      12.6.3 Product Development Activities
        12.6.3.1 IND Acceptance
  13 THERAPEUTIC ASSESSMENT
    13.1 Assessment by Stage and Product Type
    13.2 Assessment by Route of Administration
    13.3 Assessment by Stage and Route of Administration
    13.4 Assessment by Molecule Type
    13.5 Assessment by Stage and Molecule Type
  14 APPROVAL TIMELINES
    14.1 Approval Timeline for Clinical Products
  15 ANALYST INSIGHTS  
  16 INACTIVE PRODUCTS  
    16.1 Comparative Analysis
    16.2 Small Molecule Inhibitor: Evotec
      16.2.1 Product Description
      16.2.2 Product Development Activities
        16.2.2.1 Collaboration

Overview of competitive marketed and pipeline development activities for Fabry Disease is not limited to drug description and development activities but also focuses on clinical and pre-clinical results. It also includes designations, company consolidations & licensing deals, grants, technology and patent details. Therapeutic segmentation of products for Fabry Disease is done based on phase of development. The report comprises of comparative pipeline therapeutics assessment along with detailed drug profile of marketed products by development stage, therapy type, molecule type, and administration route across this indication. The report also consists of the approval timelines forecasted for the upcoming pipeline therapies. Additionally, Analyst Insight have also been focused upon to give a summary regarding the current market scenario. The detailed profiles of the dormant products have been elucidated in the complete report with the relevant reasons for their dormancy.

Secondary Research

Detail secondary study was conducted to obtain the Fabry Disease Competitive Analysis through company internal sources such as annual reports, performance presentations, press releases, etc., and external sources including trade journals, news & articles, government publications, competitor publications, sector reports, regulatory bodies publications, safety standard organizations, third-party database and other creditable publications.

The secondary research on internal and external sources is being carried out to source qualitative and quantitative information relating to each market.

  • Company websites, annual reports, quarter reports, financial reports, broker reports, investor presentations and SEC filings
  • Industry trade journals and other literature
  • National government documents, statistical databases and market reports
  • News articles, press releases and web-casts specific to the companies operating in the market
  • Several databases for patents and clinical trials

Main objective of the Fabry Disease - Competitive Analysis 2019

The current competitive marketed and pipeline trends of the Fabry Disease are pinpointed in the study. Investors can gain strategic insights to base their discretion for investments from the qualitative and quantitative analysis performed in the study. Current and future pipeline trends would determine the overall attractiveness of the market, providing a platform for the industrial participant to exploit the untapped market to benefit as first mover advantage. The quantitative objectives for the report include:

  • Detailed description of the marketed products across this indication
  • An overview of therapeutic pipeline activity for Fabry Disease across the complete product development cycle including all clinical and non-clinical stages
  • Analyse the detailed profiles of Fabry Disease therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration

Overview of competitive marketed and pipeline development activities for Fabry Disease is not limited to drug description and development activities but also focuses on clinical and pre-clinical results. It also includes designations, company consolidations & licensing deals, grants, technology and patent details. Therapeutic segmentation of products for Fabry Disease is done based on phase of development. The report comprises of comparative pipeline therapeutics assessment along with detailed drug profile of marketed products by development stage, therapy type, molecule type, and administration route across this indication. The report also consists of the approval timelines forecasted for the upcoming pipeline therapies. Additionally, Analyst Insight have also been focused upon to give a summary regarding the current market scenario. The detailed profiles of the dormant products have been elucidated in the complete report with the relevant reasons for their dormancy.

Secondary Research

Detail secondary study was conducted to obtain the Fabry Disease Competitive Analysis through company internal sources such as annual reports, performance presentations, press releases, etc., and external sources including trade journals, news & articles, government publications, competitor publications, sector reports, regulatory bodies publications, safety standard organizations, third-party database and other creditable publications.

The secondary research on internal and external sources is being carried out to source qualitative and quantitative information relating to each market.

  • Company websites, annual reports, quarter reports, financial reports, broker reports, investor presentations and SEC filings
  • Industry trade journals and other literature
  • National government documents, statistical databases and market reports
  • News articles, press releases and web-casts specific to the companies operating in the market
  • Several databases for patents and clinical trials

Main objective of the Fabry Disease - Competitive Analysis 2019

The current competitive marketed and pipeline trends of the Fabry Disease are pinpointed in the study. Investors can gain strategic insights to base their discretion for investments from the qualitative and quantitative analysis performed in the study. Current and future pipeline trends would determine the overall attractiveness of the market, providing a platform for the industrial participant to exploit the untapped market to benefit as first mover advantage. The quantitative objectives for the report include:

  • Detailed description of the marketed products across this indication
  • An overview of therapeutic pipeline activity for Fabry Disease across the complete product development cycle including all clinical and non-clinical stages
  • Analyse the detailed profiles of Fabry Disease therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration

Global Fabry Disease - Competitive Analysis 2019